With 2.38 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.42 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.605 whereas the lowest price it dropped to was $2.47. The 52-week range on NUVB shows that it touched its highest point at $4.16 and its lowest point at $1.43 during that stretch. It currently has a 1-year price target of $7.00. Beta for the stock currently stands at 1.47.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NUVB was down-trending over the past week, with a drop of -9.71%, but this was down by -6.69% over a month. Three-month performance dropped to -2.33% while six-month performance fell -21.07%. The stock gained 66.23% in the past year, while it has lost -5.64% so far this year. A look at the trailing 12-month EPS for NUVB yields -2.17 with Next year EPS estimates of -0.57. For the next quarter, that number is -0.13. This implies an EPS growth rate of -504.76% for this year and 72.83% for next year.
Float and Shares Shorts:
At present, 335.25 million NUVB shares are outstanding with a float of 229.10 million shares on hand for trading. On 2024-12-31, short shares totaled 20.94 million, which was 622.0 higher than short shares on 1732838400. In addition to Dr. David T. Hung M.D. as the firm’s Founder, President, CEO & Chairman, Dr. Gary Hattersley Ph.D. serves as its Chief Scientific Officer.
Institutional Ownership:
Through their ownership of 0.55999 of NUVB’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, NUVB reported revenue of $727000.0 and operating income of -$48101000.0. The EBITDA in the recently reported quarter was -$41450000.0 and diluted EPS was -$0.15.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NUVB since 4 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With NUVB analysts setting a high price target of 10.0 and a low target of 5.0, the average target price over the next 12 months is 7.5. Based on these targets, NUVB could surge 298.41% to reach the target high and rise by 99.2% to reach the target low. Reaching the average price target will result in a growth of 198.8% from current levels.
Analysts have provided yearly estimates in a range of -$2.06722 being high and -$2.24525 being low. For NUVB, this leads to a yearly average estimate of -$2.11667. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
